PharmaCyte Biotech reported that it has monetized its stake in Femasys Inc., increasing its combined cash and marketable securities to approximately $20 million. The transaction added roughly $6.7 million in cash, bringing the company’s liquidity from $13.44 million on July 31, 2025 to $20 million today.
Prior to the sale, PharmaCyte’s balance sheet showed $13.18 million in cash and cash equivalents and $261,853 in marketable equity securities, for a total of $13.44 million. The proceeds from the Femasys stake were deposited entirely into cash; marketable securities remained unchanged. The company originally invested $5 million in Femasys in November 2023, so the monetization represents a return on that investment.
The cash infusion is particularly important for a pre‑revenue biotech that relies on external financing to fund its clinical pipeline and regulatory activities. CEO Josh Silverman said the move “demonstrates the effectiveness of our disciplined capital allocation approach” and will give the company a stronger financial cushion as it works to lift an FDA clinical hold on its pancreatic cancer program.
With the additional liquidity, PharmaCyte can continue to advance its Cell‑in‑a‑Box platform, support ongoing clinical studies, and address the FDA’s requests without seeking immediate new capital. The company also closed a $7 million financing round in August 2025, further strengthening its balance sheet.
The transaction underscores PharmaCyte’s focus on prudent capital management and positions it to navigate the regulatory and developmental challenges ahead.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.